Purple Biotech Files 6-K with Warrant Forms and Press Release
Ticker: PPBT · Form: 6-K · Filed: Sep 5, 2025 · CIK: 1614744
Sentiment: neutral
Topics: warrants, press-release, corporate-action
TL;DR
Purple Biotech dropped a 6-K with warrant docs and a press release about 'Pri' - check it out.
AI Summary
Purple Biotech Ltd. filed a Form 6-K on September 5, 2025, reporting on its activities for the month of September 2025. The filing includes exhibits such as the form of a Pre-Funded Warrant, a Warrant, a Placement Agent Warrant, and a Securities Purchase Agreement. Additionally, it incorporates a press release announcing "Pri".
Why It Matters
This filing provides insight into Purple Biotech's recent corporate actions, including potential future equity issuances and strategic announcements, which could impact its stock valuation.
Risk Assessment
Risk Level: medium — The filing involves warrant forms and a press release, suggesting potential equity dilution or new strategic initiatives that carry inherent market risks.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the 6-K report.
- Kitov Pharma Ltd. (company) — Former name of Purple Biotech Ltd.
- Kitov Pharmaceuticals Holdings Ltd. (company) — Earlier former name of Purple Biotech Ltd.
FAQ
What is the subject of the press release included in the filing?
The press release is titled 'Purple Biotech Announces Pri', but the specific details of what 'Pri' refers to are not fully disclosed in the provided text.
What types of warrants are included as exhibits in this filing?
The filing includes the forms for a Pre-Funded Warrant, a Warrant, and a Placement Agent Warrant.
What is the principal executive office address for Purple Biotech Ltd.?
The principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
When was Purple Biotech Ltd. previously known as Kitov Pharma Ltd.?
The company changed its name from Kitov Pharma Ltd. on January 25, 2018.
What is the filing date and reporting period for this 6-K?
The filing was made on September 5, 2025, and it reports on activities for the month of September 2025.
Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2025-09-05 12:43:24
Key Financial Figures
- $18 Million — rple Biotech Announces Pricing of Up To $18 Million Public Offering This Form 6-K shall n
Filing Documents
- ea0256192-6k_purple.htm (6-K) — 16KB
- ea025619201ex4-1_purple.htm (EX-4.1) — 101KB
- ea025619201ex4-2_purple.htm (EX-4.2) — 101KB
- ea025619201ex4-3_purple.htm (EX-4.3) — 102KB
- ea025619201ex10-1_purple.htm (EX-10.1) — 223KB
- ea025619201ex99-1_purple.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-084858.txt ( ) — 565KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. September 5, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2